All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Phosphodiesterase inhibitors, which include anagrelide, cilostazol, and milrinone, prevent breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) promoting vasodilation and smooth muscle relaxation. They have also been shown to block intracellular TLR signaling, leading to apoptosis in malignant lymphocytic cells.